1
|
Abudiore O, Amamilo I, Campbell J, Eigege W, Harwell J, Conroy J, Jiboye J, Lufadeju F, Amole C, Wiwa O, Anweh D, Agbaji OO, Akanmu AS. High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria. PLoS One 2023; 18:e0284767. [PMID: 37196012 DOI: 10.1371/journal.pone.0284767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Accepted: 04/06/2023] [Indexed: 05/19/2023] Open
Abstract
Nigeria adopted dolutegravir (DTG) as part of first line (1L) antiretroviral therapy (ART) in 2017. However, there is limited documented experience using DTG in sub-Saharan Africa. Our study assessed DTG acceptability from the patient's perspective as well as treatment outcomes at 3 high-volume facilities in Nigeria. This is a mixed method prospective cohort study with 12 months of follow-up between July 2017 and January 2019. Patients who had intolerance or contraindications to non-nucleoside reverse-transcriptase inhibitors were included. Patient acceptability was assessed through one-on-one interviews at 2, 6, and 12 months following DTG initiation. ART-experienced participants were asked about side effects and regimen preference compared to their previous regimen. Viral load (VL) and CD4+ cell count tests were assessed according to the national schedule. Data were analysed in MS Excel and SAS 9.4. A total of 271 participants were enrolled on the study, the median age of participants was 45 years, 62% were female. 229 (206 ART-experienced, 23 ART-naive) of enrolled participants were interviewed at 12 months. 99.5% of ART-experienced study participants preferred DTG to their previous regimen. 32% of particpants reported at least one side effect. "Increase in appetite" was most frequently reported (15%), followed by insomnia (10%) and bad dreams (10%). Average adherence as measured by drug pick-up was 99% and 3% reported a missed dose in the 3 days preceding their interview. Among participants with VL results (n = 199), 99% were virally suppressed (<1000 copies/ml), and 94% had VL <50 copies/ml at 12 months. This study is among the first to document self-reported patient experiences with DTG in sub-Saharan Africa and demonstrated high acceptability of DTG-based regimens among patients. The viral suppression rate was higher than the national average of 82%. Our findings support the recommendation of DTG-based regimen as the preferred 1L ART.
Collapse
Affiliation(s)
| | | | | | | | | | - James Conroy
- Clinton Health Access Initiative, Abuja, Nigeria
| | | | | | | | - Owens Wiwa
- Clinton Health Access Initiative, Abuja, Nigeria
| | - Damien Anweh
- Department of Family Medicine, Federal Medical Centre Makurdi, Makurdi, Benue state, Nigeria
| | - Oche Ochai Agbaji
- Department of Medicine, Jos University Teaching Hospital, Katon Rikkos, Plateau state, Nigeria
| | - Alani Sulaimon Akanmu
- Department of Haematology and Blood transfusion, Lagos University Teaching Hospital, Lagos, Lagos State, Nigeria
| |
Collapse
|
2
|
Sam-Agudu N, Adeyemi O, Lufadeju F, Adejuyigbe E, Isah C, Ogum E, Swomen H, Yunusa F, Adamu G, Ajav-Nyior J, Galadanci H, Isah H, Jolaoso I, Charurat M. Engaging mentor mothers in a PMTCT intervention program in rural
North-Central Nigeria. Ann Glob Health 2015. [DOI: 10.1016/j.aogh.2015.02.887] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|